Armas Pharmaceuticals Incorporated, a New Jersey based multisource pharmaceutical corporation, is launching its first injectable, Azacitidine for Injection 100 MG, in the United States, it was reported yesterday.
The product is used for treating myelodysplastic syndrome, a form of cancer that leads to one or more blood cell types dropping to low numbers. It is an oncology injectable. The company aims to launch nine or more generic injectable and oral products by the first quarter of 2019, with a market size totalling more than USD430m per annum.
John Niemi, president & CEO of Armas, said, 'We are pleased to launch our first product in the US market. This will be the first of a number of high-quality pharmaceutical products that we will launch in the Armas Pharmaceutical label through our partnerships. With Armas's strong customer base and our outstanding partners, I have no doubt that Armas Pharmaceuticals will bring exceptional value with our upcoming product launches to healthcare professionals.'
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886